Johnson & Johnson Aktie News

The S&P 500 has staged an impressive rebound, but is in for more swings.

There are a number of valid reasons why many investors may be souring on the ability of equity markets to continue to rise at a 20%+ rate in the years to come.

After a 35-year career in the finance industry, including two decades as an institutional stockbroker at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing.

Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive

Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-term investors.

Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW, and ALB, have posted double-digit gains in 2025, while others lag behind. Dividend growth among Aristocrats averages 5.46% for 2025, with most constituents announcing increases, though growth is s...

Through the end of November, the year-to-date total return of the Dogs of the Dow equals 20.96%, outpacing the Dow Jones Industrial Average return of 13.86% and outpacing the broader S&P 500 Index return of 17.74%. In a sign the market seems to be broadening out, two of the top three performing Dow Dogs are health care stocks, Johnson & Johnson and Amgen. The Dogs of the Dow strategy is one whe...